EUVIMEDEUVIMED entdecken
Crossref

A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes

Antonis G. Tsamaloukas

Journal of Clinical and Medical Reviews · 2024

DOI: 10.58489/2836-2330/016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical and Medical Reviews, 2024. Verfasst von Antonis G. Tsamaloukas.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholangiocarcinoma (CCA) is a malignancy of the biliary tract epithelium and is the second most common primary liver tumor following hepatocellular carcinoma (HCC): it accounts for ~15% of primary liver cancers and ~3% of gastrointestinal malignancies. Due to late diagnoses, poor prognoses, and limited treatment strategies, CCA shows a dismal outcome with a less than 5% overall 5-year survival and only a median overall survival of ~7months. Moreover, epidemiological data show that the incidence (0.3–6 per 100,000) and mortality (1 -6 per 100,000) of CCA is increasing globally over recent decades. Cholangiocarcinoma (CCA) is associated with approximately 3,500 new cases, the second most common primary liver tumor in Germany. Cholangiocarcinoma (CCA) is classified into anatomic subtypes including intrahepatic CCA (iCCA), perihilar CCA (pCCA) and extrahepatic CCA (eCCA).

Zitieren

APA

Tsamaloukas, A. G. (2024). A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes. Journal of Clinical and Medical Reviews. https://doi.org/10.58489/2836-2330/016

Vancouver

Tsamaloukas AG. A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes. Journal of Clinical and Medical Reviews. 2024. doi:10.58489/2836-2330/016

BibTeX
@article{Tsamaloukas2024,
  author = {Tsamaloukas, Antonis G.},
  title = {A New Era for Cholangiocarcinoma Therapy – Targeting Metabolic Enzymes},
  journal = {Journal of Clinical and Medical Reviews},
  year = {2024},
  doi = {10.58489/2836-2330/016}
}
Kostenlos starten →